Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Molecular cancer therapeutics [Mol Cancer Ther] NLMUID: 101132535"" wg kryterium: JN


Tytuł :
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd.
Autorzy :
Morris J; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland. .
Wishka DG; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Lopez OD; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Rudchenko V; Alchem Laboratories Corporation, Alachua, Florida.
Huang G; Alchem Laboratories Corporation, Alachua, Florida.
Hoffman SN; Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
Borgel S; Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
Georgius K; Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
Carter J; Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
Stotler H; Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
Kunkel MW; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Collins JM; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Hollingshead MG; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Teicher BA; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 625-631.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Autorzy :
Scarpa M; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.; Department of Medicine.
Singh P; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Bailey CM; Department of Surgery and.; Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Lee JK; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Kapoor S; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Lapidus RG; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.; Department of Medicine.
Niyongere S; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.; Department of Medicine.
Sangodkar J; Division of Genetic Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Wang Y; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.; Department of Surgery and.; Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Perrotti D; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.; Department of Medicine.
Narla G; Division of Genetic Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Baer MR; The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, .; Department of Medicine.; Veterans Affairs Medical Center, Baltimore, Maryland.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 676-690. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer.
Autorzy :
Whitton B; Cancer Sciences Unit, Southampton General Hospital, Southampton, United Kingdom.; Cancer Research UK Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Okamoto H; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
Rose-Zerilli M; Cancer Sciences Unit, Southampton General Hospital, Southampton, United Kingdom.; Cancer Research UK Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Packham G; Cancer Sciences Unit, Southampton General Hospital, Southampton, United Kingdom.; Cancer Research UK Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Crabb SJ; Cancer Sciences Unit, Southampton General Hospital, Southampton, United Kingdom. .; Cancer Research UK Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 739-748. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.
Autorzy :
Lau DK; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Luk IY; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Jenkins LJ; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Martin A; NHMRC Clinical trials Centre, Sydney University, Sydney, New South Wales, Australia.; Cancer Care Centre, St. George Hospital, Kogarah, New South Wales, Australia.
Williams DS; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Schoffer KL; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Chionh F; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Buchert M; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Sjoquist K; NHMRC Clinical trials Centre, Sydney University, Sydney, New South Wales, Australia.; Cancer Care Centre, St. George Hospital, Kogarah, New South Wales, Australia.
Boussioutas A; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
Hayes SA; Kolling Institute for Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Ernst M; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Weickhardt AJ; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Pavlakis N; Kolling Institute for Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Tebbutt NC; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia. .; Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia.; Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
Mariadason JM; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia. .; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Cancer Care Centre, St. George Hospital, Kogarah, New South Wales, Australia.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 704-715. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Autorzy :
Wilson EA; Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California.
Sultana N; Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California.
Shah KN; Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California.
Elford HL; Molecules for Health, Inc., Richmond, Virginia.
Faridi JS; Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 655-664. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles.
Autorzy :
Tošić I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Biochemistry, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Heppler LN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Egusquiaguirre SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Boehnke N; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Correa S; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Costa DF; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Moore EAG; Department of Chemistry, Molecular and Cell Biology, University of California at Berkeley, Berkeley, Massachusetts.
Pal S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Richardson DS; Harvard Center for Biological Imaging, Harvard University, Cambridge, Massachusetts.
Ivanov AR; Department of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, Massachusetts.
Haas-Kogan DA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nomura DK; Department of Chemistry, Molecular and Cell Biology, University of California at Berkeley, Berkeley, Massachusetts.
Hammond PT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.; Institute for Soldier Nanotechnology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Frank DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. .; Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 726-738. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies.
Autorzy :
Herrick WG; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
Kilpatrick CL; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
Hollingshead MG; Biological Testing Branch, NCI, Frederick, Maryland.
Esposito D; Protein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Gross AM; Pediatric Oncology Branch, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland.
Johnson BC; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Widemann BC; Pediatric Oncology Branch, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland.
Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland.
Parchment RE; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
Srivastava AK; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 749-760. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma.
Autorzy :
Shigeta S; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Lui GYL; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Shaw R; SEngine Precision Medicine, Seattle, Washington.
Moser R; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gurley KE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Durenberger G; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington.
Rosati R; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington.
Diaz RL; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington.
Ince TA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, and New York Presbyterian Brooklyn Methodist Hospital, New York.
Swisher EM; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington.
Grandori C; SEngine Precision Medicine, Seattle, Washington.; Cure First, Seattle, Washington.
Kemp CJ; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 691-703. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.
Autorzy :
Garvey DR; Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
Chhabra G; Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
Ndiaye MA; Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
Ahmad N; Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin. .; William S. Middleton VA Medical Center, Madison, Wisconsin.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 632-640. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Autorzy :
Lo AA; Genentech Inc., South San Francisco, California.
Johnston J; Genentech Inc., South San Francisco, California.
Li J; Genentech Inc., South San Francisco, California.
Mandikian D; Genentech Inc., South San Francisco, California.
Hristopoulos M; Genentech Inc., South San Francisco, California.
Clark R; Genentech Inc., South San Francisco, California.
Nickles D; Genentech Inc., South San Francisco, California.
Liang WC; Genentech Inc., South San Francisco, California.
Hötzel K; Genentech Inc., South San Francisco, California.
Dunlap D; Genentech Inc., South San Francisco, California.
Pham T; Genentech Inc., South San Francisco, California.
Cai H; Genentech Inc., South San Francisco, California.
Ovacik M; Genentech Inc., South San Francisco, California.
Bravo-Perez D; Genentech Inc., South San Francisco, California.
Mai E; Genentech Inc., South San Francisco, California.
Slaga D; Genentech Inc., South San Francisco, California.
Ellerman D; Genentech Inc., South San Francisco, California.
Ziai J; Genentech Inc., South San Francisco, California.
Totpal K; Genentech Inc., South San Francisco, California.
Lee G; Genentech Inc., South San Francisco, California.
Boswell CA; Genentech Inc., South San Francisco, California.
Payandeh J; Genentech Inc., South San Francisco, California.
Wu Y; Genentech Inc., South San Francisco, California.
Junttila TT; Genentech Inc., South San Francisco, California. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 716-725. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET , VEGFR2 , and IGFBP2 .
Autorzy :
Bagheri-Yarmand R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. .
Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ye L; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shiny Jebaraj Y; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Martinez JA; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ma J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tarapore RS; Oncoceutics, Inc., Philadelphia, Pennsylvania.
Allen JE; Oncoceutics, Inc., Philadelphia, Pennsylvania.
Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Williams MD; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gagel RF; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 665-675. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer.
Autorzy :
Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. .
Zhao Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Knott AR; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Musteanu M; Experimental Oncology, Molecular Oncology Program, CNIO, Madrid, Spain.; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Complutense University of Madrid, Spain.
Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. .; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 641-654. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Expanding the repertoire for "large small molecules" : Prodrug ABBV-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers.
Autorzy :
Salem AH; Clinical Pharmacology and Pharmacometrics, AbbVie Inc.
Tao ZF; Oncology Discovery, AbbVie, Inc.
Bueno OF; Oncology Development, AbbVie, Inc.
Chen J; Development Sciences, AbbVie, Inc.
Chen S; Development Sciences, AbbVie, Inc.
Edalji R; Protein Biochemistry, AbbVie (United States).
Elmore SW; Cancer Research, Abbott Laboratories.
Fournier KM; Oncology Development, AbbVie, Inc.
Harper KC; Development Sciences, AbbVie, Inc.
Hong R; Development Sciences, AbbVie, Inc.
Jenkins GJ; Development Sciences, AbbVie, Inc.
Ji J; Development Sciences, AbbVie, Inc.
Judge RA; Structural Biology, AbbVie, Inc.
Kalvass JC; Development Sciences, AbbVie, Inc.
Klix RC; Development Sciences, AbbVie, Inc.
Ku YY; Development Sciences, AbbVie, Inc.
Leverson JD; Oncology Development, AbbVie, Inc.
Marks RA; Oncology Development, AbbVie, Inc. (retired).
Marsh KC; Development Sciences, AbbVie, Inc.
Menon RM; Clinical Pharmacology and Pharmacometrics, AbbVie Inc.
Park CH; Protein Biochemistry, AbbVie, Inc. (retired).
Phillips DC; Oncology Discovery, AbbVie Inc.
Pu YM; Development Sciences, AbbVie, Inc.
Rosenberg SH; AbbVie, Inc.
Sanzgiri YD; Development Sciences, AbbVie, Inc.
Sheikh AY; Development Sciences, AbbVie, Inc.
Shi Y; Development Sciences, AbbVie, Inc.
Stolarik D; Oncology Discovery, AbbVie, Inc.
Suleiman AA; , AbbVie, Inc.
Wang X; Oncology Discovery, AbbVie, Inc.
Zhang GGZ; Development Sciences, AbbVie, Inc.
Catron ND; Development Sciences, AbbVie, Inc.
Souers AJ; Oncology Discovery, AbbVie, Inc. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling.
Autorzy :
Kizilbash SH; Department of Oncology, Mayo Clinic .
Gupta SK; Department of Radiation Oncology, Mayo Clinic.
Parrish KE; Pharmaceutics, University of Minnesota.
Laramy JK; Pharmaceutics, University of Minnesota.
Kim M; Pharmaceutics, University of Minnesota.
Gampa G; Pharmaceutics, University of Minnesota.
Carlson BL; Department of Radiation Oncology, Mayo Clinic.
Bakken KK; Department of Radiation Oncology, Mayo Clinic.
Mladek AC; Department of Radiation Oncology, Mayo Clinic.
Schroeder MA; Department of Radiation Oncology, Mayo Clinic.
Decker PA; Mayo Clinic.
Elmquist WF; Pharmaceutics, University of Minnesota.
Sarkaria JN; Department of Radiation Oncology, Mayo Clinic.
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Enhancing proteotoxic stress in leiomyosarcoma cells triggers mitochondrial dysfunctions, cell death and anti-tumor activity in vivo.
Autorzy :
Iuliano L; Medicine, UNIVERSITA' DI UDINE.
Drioli S; di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste.
Pignochino Y; Clinical and Biological Sciences, University of Turin.
Cafiero CM; di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste.
Minisini M; Medicine, UNIVERSITA' DI UDINE.
D'Este F; Medicine, UNIVERSITA' DI UDINE.
Picco R; Medicine, UNIVERSITA' DI UDINE.
Dalla E; Medicine, UNIVERSITA' DI UDINE.
Giordano G; Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS.
Grignani G; Medical Oncology, Candiolo Cancer Institute - FPO, IRCCS.
Di Giorgio E; Medicine, UNIVERSITA' DI UDINE.
Benedetti F; di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste.
Felluga F; di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste.
Brancolini C; of Medicine, UNIVERSITA' DI UDINE .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Targeted therapy to β3 integrin reduces chemoresistance in breast cancer bone metastases.
Autorzy :
Fox GC; Department of Medicine, Oncology Division, Washington University in St. Louis School of Medicine.
Su X; Medicine, Division of Oncology, Washington University in St. Louis School of Medicine.
Davis JL; Department of Medicine - Division of Molecular Oncology, Washington University in St. Louis School of Medicine.
Xu Y; Medicine, Oncology Division, Washington University in St. Louis School of Medicine.
Kwakwa KA; Medicine (Oncology), Washington University in St. Louis School of Medicine.
Ross MH; Medicine, Division of Oncology, Washington University in St. Louis School of Medicine.
Fontana F; Medicine, Washington University in St. Louis.
Xiang J; Medicine, Oncology Division, Washington University in St. Louis School of Medicine.
Esser AK; Medicine, Division of Oncology, Washington University in St. Louis School of Medicine.
Cordell E; Medicine, Oncology Division, Washington University in St. Louis School of Medicine.
Pagliai K; Medicine, Oncology Division, Washington University in St. Louis School of Medicine.
Dang HX; Internal Medicine, Washington University in St. Louis.
Sivapackiam J; Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine.
Stewart SA; Department of Cell Biology and Physiology, Washington University in St. Louis School of Medicine.
Maher CA; Oncology Division, Washington University in St. Louis School of Medicine.
Bakewell SJ; Preclinical Development, Intezyne Technologies, Inc.
Sharma V; Mallinckrodt Institute of Radiology; Neurology; Biomedical Engineering, School of Engineering and Applied Science, Washington University in St. Louis School of Medicine.
Achilefu S; Radiology, Washington University in St. Louis.
Veis DJ; Department of Medicine, Division of Bone and Mineral Diseases; Department of Pathology, Washington University in St. Louis School of Medicine.
Lanza GM; Medicine, Washington University in St. Louis.
Weilbaecher KN; Internal Medicine, Washington University in St. Louis School of Medicine .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
RNA-binding protein polymorphisms as novel biomarkers to predict outcomes of metastatic colorectal cancer: A meta-analysis from TRIBE, FIRE-3 and MAVERICC.
Autorzy :
Arai H; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Cao S; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Battaglin F; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Wang J; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Kawanishi N; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Tokunaga R; Division of Medical Oncology,, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Loupakis F; Department of Oncology, Veneto Institute of Oncology IOV - IRCCS.
Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin.
Soni S; Division of Medical Oncology, University of Southern California.
Zhang W; Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California.
Mancao C; Oncology Biomarker Development, Genentech Inc.
Salhia B; Translational Genomics, Keck School of Medicine/USC.
Mumenthaler SM; Center for Applied Molecular Medicine, University of Southern California.
Cremolini C; Department of Oncology, Transplantes and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and University of Pisa.
Heinemann V; Department of Medical Oncology and Comprehensive Cancer Center, University of Munich.
Falcone A; Department of Oncology, Transplantes and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and University of Pisa.
Millstein J; Preventive Medicine, University of Southern California.
Lenz HJ; Medicine, Norris Comprehensive Cancer Center, University of Southern California .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation.
Autorzy :
Wang W; Medical Sciences, Indiana University School of Medicine.
Fang F; Indiana University Bloomington.
Ozes A; Molecular and Cellular Biochemistry, Indiana University Bloomington.
Nephew KP; Medical Sciences, Indiana University School of Medicine .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3Kg inhibition.
Autorzy :
Carnevalli LS; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom) .
Taylor MA; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
King M; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Coenen-Stass AM; Research and Early Development, AstraZeneca (United Kingdom).
Hughes AM; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Bell S; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Proia TA; Bioscience, Oncology R&D, AstraZeneca (United States).
Wang Y; Bioscience, Oncology R&D, AstraZeneca (United States).
Ramos-Montoya A; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Wali N; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Carroll D; Research and Early Development, AstraZeneca (United Kingdom).
Singh M; Bioscience, Oncology R&D, AstraZeneca (United States).
Moschetta M; Early Development, AstraZeneca (United Kingdom).
Morentin Gutierrez P; IMED Oncology, AstraZeneca (United Kingdom).
Gardelli C; Medicinal Chemistry, Research and Early Development, Respiratory& Immunology, AstraZeneca.
Critchlow SE; BIoscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Klinowska T; Oncology R&D, AstraZeneca (United Kingdom).
Fawell SE; Oncology, IMED Biotech Unit, AstraZeneca R&D Boston.
Barry ST; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca (United Kingdom).
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies